Plasma Lipidomic Signature of Rectal Adenocarcinoma Reveals Potential Biomarkers

Frontiers in Oncology

Carlos Augusto Real Martinez¹  Laura Credidio¹  Cláudio Saddy Rodrigues Coy¹  Célio Fernando Figueiredo Angolini²  Marcos Nogueira Eberlin²  Márcia Cristina Fernandes Messias³  Giovana Colozza Mecatti³  Patrícia de Oliveira Carvalho³ 

[1] Department of Surgery, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil;Institute of Chemistry, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil;Laboratory of Multidisciplinary Research, São Francisco University (USF), Bragança Paulista, São Paulo, Brazil;

关键词: lipidomic;    rectal adenocarcinoma;    biomarkers;    lipoperoxidation;    mass spectrometry;   

DOI  :  10.3389/fonc.2017.00325

来源: DOAJ

【 摘 要 】

BackgroundRectal adenocarcinoma (RAC) is a common malignant tumor of the digestive tract and survival is highly dependent upon stage of disease at diagnosis. Lipidomic strategy can be used to identify potential biomarkers for establishing early diagnosis or therapeutic programs for RAC.ObjectiveTo evaluate the lipoperoxidation biomarkers and lipidomic signature in the plasma of patients with RAC (n = 23) and healthy controls (n = 18).MethodsLipoperoxidation was evaluated based on malondialdehyde (MDA) and F2-isoprostane levels and the lipidomic profile obtained by gas chromatography and high resolution mass spectrometry (ESI-q-TOF) associated with a multivariate statistical technique.ResultsThe most abundant ions identified in the RAC patients were those of protonated phosphatidylcholine and phosphatidylethanolamine. It was found that a lisophosphatidylcholine (LPC) plasmalogen containing palmitoleic acid [LPC (P-16:1)], with highest variable importance projection score, showed a tendency to be lower in the cancer patients. A reduction of n − 3 polyunsaturated fatty acids was observed in the plasma of these patients. MDA levels were higher in patients with advanced cancer (stages III/IV) than in the early stages groups and the healthy group (p < 0.05). No differences in F2-isoprostane levels were observed among these groups.ConclusionThis study shows that the reduction in plasma levels of LPC plasmalogens associated with an increase in MDA levels may indicate increased oxidative stress in these patients and identify the metabolite LPC (P-16:1) as a putatively novel lipid signature for RAC.

【 授权许可】

Unknown